Demand Fundamental	Value	Score	Rating
Qtr/Qtr Revenue Growth	Members Only
Qtr/Qtr Earnings Growth	Members Only
Year/Year Revenue Growth	Members Only
Year/Year Earnings Growth	Members Only
Multi-Year Revenue Growth	Members Only
Multi-Year Earnings Growth	Members Only
Relative PE Ranking	Members Only
Return on Equity	Members Only
Yield	Members Only
Institutional Holding	Members Only
Stock Price	Members Only
Relative Fundamental Ranking	Members Only
Total Score	Members Only

Demand Technical	Value	Score	Rating
Recommended Condition	Members Only
Trading Zone	Members Only
Average Trading Volume	Members Only
Industry Bull/Bear Condition	Members Only
Sector Bull/Bear Condition	Members Only
Current Signal Start Date	Members Only
Total Score	Members Only

Simcere Pharmaceutical Group develops, manufactures, and markets branded generic and proprietary pharmaceuticals in China. Its principal branded generic pharmaceuticals consist of edaravone injections to treat strokes under the Bicun and Yidasheng brands- generic prescription amoxicillin antibiotics under the Zailin brand- anti-inflammatory pain reliever and analgesic drugs to treat rheumatoid arthritis and osteoarthritis under the Yingtaiqing brand- and sustained release implants under the Sinofuan brand. The company's other branded generic pharmaceuticals include generic over-the-counter (OTC) anti-diarrhea pharmaceuticals under the Biqi brand- amoxicillin and clavulanate potassium tablets, granules, and injection to treat infections under the Anqi brand- cefaclor in dry suspension antibiotics to treat infections under the Zaike brand- and OTC herbal medicines to treat coughs under the Simcere Kechuanning brand. It manufactures and sells 51 principal pharmaceuticals under various brands. The company also distributes prescription pharmaceuticals manufactured by independent third parties. As of March 31, 2011, it had approximately 13 product candidates under development, including treatments for cancer, cerebrovascular diseases, infections, rheumatoid arthritis, and nausea and vomiting associated with chemotherapy. The company sells its products through pharmaceutical distributors to other distributors, hospitals, and retail pharmacies in China, as well as markets its vaccines to Centers for Disease Control. It has a strategic partnership with Sun Yat-Sen University Cancer Center to research anti-cancer treatments- an agreement with OSI Pharmaceuticals, Inc. to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China- and a strategic partnership with Bristol-Myers Squibb to co-develop BMS-817378, a pre-clinical small molecule MET/VEGFR-2 inhibitor. The company was founded in 1995 and is headquartered in Nanjing, the People's Republic of China.